Group 1 - Daikin Heavy Industries' subsidiary signed a contract worth approximately 1.339 billion yuan for an offshore wind farm project in Europe, accounting for 35.41% of the company's audited revenue for 2024 [1] Group 2 - Zhaoyi Innovation announced that several board members and senior management plan to reduce their holdings by a total of 249,000 shares, due to personal financial needs, with the reduction period set from December 15, 2025, to March 14, 2026 [2] Group 3 - Jushi Chemical received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws, while the company's operations continue normally [3][6] Group 4 - Chaozhuo Aerospace announced a stock suspension due to major matters being planned by its controlling shareholders, which may lead to a change in control [4] Group 5 - Heng Rui Medicine received approval for clinical trials of SHR-1139 injection, a biopharmaceutical with no similar products approved for sale domestically or internationally, with a cumulative R&D investment of approximately 100.13 million yuan [5] Group 6 - Huayou Pharmaceutical's HYP-6589 tablet for treating advanced non-small cell lung cancer received a clinical trial application acceptance notice, with no similar products approved for sale [8] Group 7 - Renfu Pharmaceutical's application for the marketing license of Dexamethasone L-amphetamine capsules was accepted, aimed at treating ADHD, with a cumulative R&D investment of approximately 90 million yuan [10] Group 8 - Huibo Group won a bid for a 1.596 billion yuan project for the restoration of an oil field in Iraq [10]

Core Viewpoint - Two listed companies, Jushi Chemical and Haosai, have been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1][2]. Group 1: Jushi Chemical - Jushi Chemical announced on November 21, 2025, that it received a notice of investigation from the CSRC due to suspected violations of information disclosure [1]. - The company stated that all business activities are operating normally and it will actively cooperate with the CSRC [2]. Group 2: Haosai - Haosai also received a notice of investigation from the CSRC for suspected information disclosure violations, and it will cooperate with the investigation while ensuring compliance with disclosure obligations [2][4]. - The company reported a revenue of 265 million yuan for the first three quarters of the year, a decrease of 29.79% year-on-year, and a net loss of 26.31 million yuan, a decrease of 523.96% year-on-year [4]. - The decline in revenue is attributed to fluctuations in demand in the lighting engineering industry due to adjustments in investment rhythms in infrastructure and real estate [4]. - Haosai's strategic development framework includes "Three Smart One Network" and "Haonenghui New Energy," focusing on digital technology and comprehensive management services for green energy solutions [4]. - The company faced legal issues, including a public prosecution against its former chairman for bribery, resulting in a fine of 7 million yuan and a prison sentence for the chairman [7][8]. - On November 17, 2025, Haosai received a criminal appeal notice from the Wuhan New District People's Procuratorate, indicating uncertainty in the final judgment [9].

Core Points - Haosai has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure regulations [2][4] - The company's actual controller, Dai Baolin, has been arrested for alleged unit bribery, leading to further scrutiny of the company's operations [5][6] Group 1: Investigation Details - On November 21, Haosai announced it received a notice of investigation from the CSRC due to suspected information disclosure violations [2] - The investigation follows Dai Baolin's arrest by public security authorities for alleged unit bribery, which has raised concerns about the company's governance and internal controls [5][6] Group 2: Company Operations - Haosai stated that it will actively cooperate with the investigation and that its business operations are currently normal and orderly [4] - The company has been under negative scrutiny since December of the previous year, with regulatory bodies highlighting deficiencies in its information disclosure practices [5][6] Group 3: Regulatory Actions - The Beijing Securities Regulatory Bureau issued a warning letter to Haosai for failing to fulfill its information disclosure obligations [6][7] - The Shenzhen Stock Exchange also sent a regulatory letter to Haosai and its responsible personnel, urging strict compliance with relevant laws and regulations regarding information disclosure [8] Group 4: Company Profile - Haosai's main business includes precision stamping molds and metal structural components for new energy vehicles, fuel vehicles, energy storage equipment, and communication devices [8] - As of November 21, Haosai's stock price was reported at 16.21 yuan per share, with a total market value of 2.437 billion yuan [8]

Core Viewpoint - 聚石化学 and 豪尔赛 are both under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact their operations and investor confidence [1][5]. Company Overview - 聚石化学 specializes in the research, production, and sales of new chemical materials, with products including modified plastic particles, automotive profiles, optical materials, and flame retardants, among others [3]. - 豪尔赛 focuses on technology innovation, developing smart lighting, smart cultural tourism, and smart urban areas, along with a digital twin integration network platform [7]. Financial Performance - 聚石化学 reported a revenue of 986.58 million yuan for Q3 2025, a decrease of 0.81% year-on-year, with a net profit of 2.89 million yuan [4]. - 豪尔赛 achieved a revenue of 106.94 million yuan for Q3 2025, an increase of 31.34% year-on-year, with a net profit of 740.11 thousand yuan, reflecting a significant growth of 599.72% [8].

Core Viewpoint - Two A-share companies, 聚石化学 and 豪尔赛, have been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [2][5]. Group 1: 聚石化学 (688669) - On November 21, 2025, 聚石化学 received a notice from the CSRC regarding the investigation for suspected information disclosure violations [2]. - The company reported a revenue of 987 million yuan in Q3 2025, a year-on-year decrease of 0.81%, with a net profit attributable to shareholders of 2.89 million yuan [4]. - 聚石化学 specializes in the research, production, and sales of new chemical materials, with products used in various industries including automotive, electronics, and healthcare [4]. Group 2: 豪尔赛 (002963) - 豪尔赛 also received a notice from the CSRC for suspected information disclosure violations [5]. - The company reported a revenue of 107 million yuan in Q3 2025, a year-on-year increase of 31.34%, and a net profit attributable to shareholders of 7.40 million yuan, a significant increase of 599.72% [8]. - 豪尔赛 focuses on technology innovation in areas such as smart lighting and digital twin networks, and has been under scrutiny due to previous issues related to corporate governance and internal controls [7][8].

Core Viewpoint - Haosai Technology Group Co., Ltd. has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws [1] Group 1: Investigation Details - The CSRC has decided to conduct a formal investigation into the company based on the Securities Law of the People's Republic of China and the Administrative Penalty Law [1] - The company will actively cooperate with the CSRC during the investigation and will adhere to relevant laws and regulations for timely information disclosure [1] Group 2: Company Operations - Haosai Technology states that its business operations are currently normal and orderly, and the investigation will not have a significant impact on its management and operations [1] - The company has designated the Securities Times and the Giant Tide Information Network as its official information disclosure media [1]

Core Viewpoint - Haosai (002963) has received a notice of investigation from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, but the company asserts that its operations remain normal and orderly, and the investigation will not significantly impact its management and operations [1] Group 1 - On November 21, Haosai announced the receipt of the CSRC's "Notice of Investigation" [1] - The investigation is due to alleged violations of information disclosure regulations [1] - Haosai's stock price fell by 5.32% to 16.21 yuan at market close on the day of the announcement [1]

盘面上，截至 今日 收盘， 豪尔赛跌5.32%，报16.21元。 编辑 ｜心一 11月21日，豪尔赛（002963）公告称， 公司于近日收到中国证监会下发的《立案告知书》，因涉嫌 信息披露违法违规，中国证监会对公司进行立案。 豪尔赛表示， 目前，公司各项经营活动正常有序开展，本次立案不会对公司经营和管理造成重大影 响。 ...

Regulatory Actions - Haosai is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, but the company states that its operations remain normal and the investigation will not significantly impact management [2] - Central Plaza and its executives received a warning letter from the Jiangsu Securities Regulatory Bureau for failing to timely disclose significant litigation progress, which led to inaccurate financial reporting [3] - Guolian Aquatic received a warning letter from the Guangdong Securities Regulatory Bureau for non-operating fund occupation by its controlling shareholder, which was not disclosed in a timely manner [9] Corporate Actions - Jiarong Technology is planning a major asset restructuring and has suspended trading of its shares, expected to last no more than 10 trading days [4] - Maiwei Co. announced a debt restructuring totaling 371 million yuan, with an expected loss of 85.465 million yuan, aimed at improving cash flow and reducing receivables risk [5] - New World plans to use up to 850 million yuan of idle fundraising to purchase financial products or deposits, with a total of 575 million yuan already invested in such products [6] Legal Matters - Sunshine Nuohuo's lawsuit against Hengsheng Pharmaceutical has entered the second instance, with the original claim amounting to 20 million yuan and a counterclaim of 7.4073 million yuan [8] Product Development - Huyou Pharmaceutical's HYP-6589 tablet has received acceptance for clinical trial applications for treating advanced non-small cell lung cancer [7] - Renfu Pharmaceutical's application for the marketing license of a new ADHD treatment has been accepted, with no similar products currently available in the domestic market [10] Strategic Partnerships - Jindi Co. signed a strategic cooperation letter of intent with Dongpei Co. to explore collaboration on humanoid robot harmonic reducer assemblies and key components [11] Share Buybacks and Holdings - Yuyuan Co. has repurchased 1 million A-shares for a total of approximately 5.3864 million yuan as part of a buyback plan [12] - Yuheng Pharmaceutical's executives increased their holdings by 1.12%, acquiring a total of 25 million shares [13] Major Contracts - Huayou Huibo has been awarded a contract worth 225 million USD for the Iraq NaftKhana oilfield project, which is expected to significantly impact future earnings [16] - Dajin Heavy Industry's subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, representing 35.41% of the company's expected annual revenue [17]

Group 1 - The core point of the article is that Haosai (002963.SZ) has received a notice of investigation from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1] - The investigation is based on the provisions of the Securities Law of the People's Republic of China and the Administrative Penalty Law [1] - The CSRC has officially initiated a case against the company due to these allegations [1]